By intravenously injecting purified CD34+CD38+CD19+ or CD34+CD38−CD19+ cells from B-precursor ALL patients, they successfully demonstrated the leukemia-initiating capacity of both cell types [22]. This evidence concerns the gene CD34 and leukemia.